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Abstract
Hepatitis B e-antigen (HBeAg)-negative chronic HBV infection is highly prevalent in several parts of the world, including India, with the
clinical spectrum ranging from inactive carrier (IC) state to chronic ‘e-negative’ hepatitis B (CHB) and culminating in advanced liver dis-
ease such as cirrhosis (LC). The present study has for the ﬁrst time investigated the natural diversity of HBV belonging to genotype D
in treatment-naı¨ve Indian patients representing the above phases of HBeAg-negative infection to identify candidate mutations associated
with each disease state. Studies of full-length HBV/D sequences revealed that the progressive accumulation and persistence of mutations
in basal core promoter, negative regulatory element, Pre-core region, the B- and T-cell epitopes of X protein as well as deletions in the
PreS region contribute signiﬁcantly to disease progression from IC through CHB to LC. In addition, the development of CHB was asso-
ciated with a signiﬁcant increase in viral variants characterized by mutations in enhancer II, preS1 promoter, T-cell epitope of core and
B-cell epitope region of PreS1. While few of the mutations were previously reported in the context of HBV genotypes B and C, others
had not been documented before. Our results thus highlight a distinct pattern of mutation in HBV/D that may help in predicting clinical
outcomes of HBeAg-negative infection and have implications for better clinical management of the patients.
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Introduction
During the course of chronic HBV infection, HBeAg sero-
conversion to its antibody (anti-HBe) is known to lead to a
favourable outcome in patients and coincides with normaliza-
tion of liver biochemical tests, loss or decrease of serum
HBV DNA, subsidence of hepatic inﬂammation and clinical
remission [1,2]. Patients with such quiescent infection are
commonly referred to as ‘inactive carriers’ (IC) [3]. How-
ever, active hepatitis may develop in up to one-third of IC
without reversion of HBeAg in their serum [4,5]. This phase,
called ‘HBeAg-negative chronic hepatitis’ (CHB), is character-
ized by absence of HBeAg, detectable levels of HBV DNA,
raised serum alanine aminotransferase (ALT), and histological
ﬁndings of continued necroinﬂammation of the liver [6]. The
sequelae of e-negative CHB may include mild to moderate
ﬁbrosis, cirrhosis or even hepatocellular carcinoma (HCC)
[7]. In recent years several reports have suggested an
increasing incidence of HBeAg-negative CHB worldwide,
including in India [6,8]. Different mutations arise in the HBV
genome during chronic infection, which had been attributed
to error-prone viral replication and directional selection by
host immunity. There is growing evidence that viral polymor-
phism is one of the critical factors that inﬂuence disease pro-
gression and outcome. Of particular importance were the
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double mutations, A1762T and G1764A, in the basal core
promoter (BCP) of HBV and deletions in the preS2 and X
regions that were increasingly prevalent with advancement of
disease severity [9,10]. However, these studies were mostly
carried out on HBV belonging to genotypes B and C that
prevail in eastern Asia and the ﬁndings may not be general-
ized to populations that are infected with other genotypes of
HBV, given that different genotypes have unique patterns of
mutations and distinct propensities for selection of mutants
[11]. HBV belonging to genotype D has a wide geographical
distribution and predominates in the Mediterranean area,
Middle East and India [12]. The present study aims to carry
out a genome-wide analysis of HBV of genotype D from
treatment-naı¨ve, chronic e-negative Indian patients presenting
(i) as IC, (ii) with CHB and (iii) with liver cirrhosis (LC) to
assess how the temporal acquisition and persistence of dif-
ferent mutations inﬂuence the evolving clinical landscape of
e-negative HBV infection.
Materials and Methods
Collection of samples and storage
Sixty treatment-naı¨ve HBV-infected patients, having HBsAg
positivity (>6 months) but negative for HBeAg and repre-
senting different phases of chronic e-negative infection, were
included in the study from the Hepatology Clinic of the Insti-
tute of Post Graduate Medical Education and Research, Kolk-
ata, between August 2009 and July 2010. Patients with other
viral infections and history of signiﬁcant alcohol intake were
excluded. The IC were characterized by consistently normal
levels of ALT (2–45 IU/L) and AST (2–40 IU/L) during four
consecutive follow-ups within a period of 1 year prior to
enrollment and had low HBV DNA (<104 copies/mL). The e-
negative CHB patients were diagnosed on the basis of serum
HBV DNA >104 copies/mL, persistent or intermittent eleva-
tion of ALT levels, histologically documented moderate or
severe necroinﬂammation and absence of cirrhosis. LC was
diagnosed by histological analysis of liver biopsy tissues or by
ultrasonography and supplemented with clinical evidence of
portal hypertension. From each participant 5 mL blood was
collected, and serum was isolated and stored in a )80C
refrigerator until use. The study was approved by the Institu-
tional Ethical Review Committee.
Testing of serological markers and liver enzymes
Serum samples were tested for ALT/AST levels, total pro-
tein, albumin, alkaline phosphatase, prothrombin time (INR)
and bilirubin as well as for serological markers (HBsAg,
HBeAg and anti-HBe) using commercially available kits.
HBV DNA isolation and quantiﬁcation
HBV DNA was extracted from 200 lL serum using the QIA-
amp DNA Mini Kit (Qiagen, Valencia, CA, USA). Viral load
was determined by real-time PCR using SYBR Green PCR
Master mix (Applied Biosystems, Foster City, CA, USA) [13].
The lower limit of detection was 250 copies/mL.
Ampliﬁcation of full-length HBV genome sequencing and
phylogenetic analysis
Full-length HBV DNA (c. 3.2 kb) was ampliﬁed by the one-
step ampliﬁcation method described by Gunther et al. [14].
In the case of a low HBV DNA level, a second round nested
PCR was performed using two different primer sets, MP1
with R5 and F3 with MP2 (Table 1). The PCR products were
sequenced directly with different internal primers (Table 1)
using the BigDye terminator v3.1 cycle sequencing kit
(Applied Biosystems) on an automated DNA sequencer.
Sequence editing and analysis were performed using Seq-
scape V2.5 software.
HBV sequences thus obtained were compared with repre-
sentative sequences of ten HBV genotypes (A–J) retrieved
from GenBank. Alignments were carried out using CLU-
STALX software and a phylogenetic tree was constructed by
the neighbour joining (NJ) method using the Kimura 2
parameter model in MEGA software version 5. To conﬁrm
the reliability of the phylogenetic tree analysis, bootstrap
resampling and reconstruction were carried out 5000 times.
Sequence variability was analysed with the help of multiple
alignment data.
Statistical analysis
Data were analysed using SPSS (ver10.1) software. The
results were presented as median (range) or mean ± stan-
dard deviation (SD) as appropriate. One-way ANOVA or
the Kruskal–Wallis test were used, as appropriate, for group
comparisons of quantitative variables depending on whether
TABLE 1. Primers used in this study
Primer
name Primer sequences
Location
(nt)a
F1b 5¢-CACAAGAGGACTCTTGGACT-3¢ 1653–1672
F3b,c 5¢-CGCCTCATTTTGTGGGTCAC-3¢ 2801–2820
F4b 5¢-CTCAGGCCATGCAGTGGAA-3¢ 3164–3182
F5b 5¢-GATGTGTCTGCGGCGTTTTA-3¢ 376–395
R1b 5¢-CCACCTTATGAGTCCAAGG-3¢ 2457–2475
R3b 5¢-AACTGGAGCCACCAGCAG-3¢ 57–74
R5b,c 5¢-AAAGCCCAAAAGACCCACAAT-3¢ 996–1016
MP1c 5¢-GAGCTCTTCTTTTTCACCTCTGCCTAATCA-3¢ 1821–1841
MP2c 5¢-GAGCTCTTCAAAAAGTTGCATGGTGCTGG-3¢ 1806–1825
aNt positions are given according to HBV sequence with accession no.
AF121242 obtained from GenBank.
bPrimer used for sequencing.
cPrimer used for nested PCR.
CMI Ghosh et al. Mutations in HBV/D in different phases of e-negative infection E413
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E412–E418
the variances of the groups were similar or not. P-trend test
and Fisher’s exact test were performed for evaluating the
role of a speciﬁc mutation with disease progression and to
make pairwise group comparisons of mutation frequencies,
respectively. For all tests, a p-value <0.05 was considered
signiﬁcant.
Nucleotide sequence accession numbers
The nucleotide sequences of 40 HBV/D isolates are available
in the GenBank database (http://www.ncbi.nlm.nih.gov/GenBank/
index.html) under accession numbers JN664909–JN664948.
Results
Clinical, serological and demographic data
Based on clinical, biochemical, serological and histological
assessment, and HBV DNA levels, 16 out of 60 HBeAg-nega-
tive patients were categorized as IC, 20 as CHB and 24 as
LC (Table 2).
HBV genotypes
The phylogenetic analysis of 60 complete HBV sequences
obtained from HBeAg-negative patients revealed the pres-
ence of three distinct genotypes, D, A and C (Fig. 1). Forty
out of 60 HBV isolates (66.66%) belonged to genotype D
while 9 (15%) were of genotype A and 11 (18.30%) clustered
with genotype C. Subsequent analyses of viral mutation with
respect to different disease stages were carried out exclu-
sively on 40 HBV/D isolates, of which 14 strains were from
IC and 13 each from CHB and LC.
Mutational patterns in HBV/D in different phases of e-nega-
tive infection
Promoter/regulatory regions. The expression of the HBV genes
is controlled by four different promoters, two enhancers
(EnhI (nt. 1074–1234) and EnhII (nt. 1636–1741)) and a
negative regulatory element (NRE; nt. 1613–1636). The com-
monly described double mutations in BCP (A1762T and
G1764A) that cause reduced level of HBeAg expression
were observed in 11 out of 40 (27.5%) HBV/D from HBeAg-
negative subjects. These mutations were present in 30.76%
of CHB and 53.84% of LC but were absent in IC
(Ptrend = 0.002; Table 3). Another BCP mutation, C1773T,
was found in CHB (30.76%) and LC (38.46%) but was unde-
tected in IC. Overall, the combination of mutations
A1762T+G1764A+C1773T increased signiﬁcantly during the
progressive phases from IC to LC (Ptrend = 0.009). Within
EnhII, the frequency of C1694T was found to increase signiﬁ-
cantly in CHB (46.15%) as compared with IC (7.14%) (PIC vs.
CHB = 0.029) although it declined among LC (23.07%;
Table 3). An increasing prevalence of the A1635T/G muta-
tion in NRE was also noted in advancing clinical stages of
e-negative infection, being 14.28% in IC, 46.15% in CHB and
53.85% in LC (Ptrend = 0.033) (Table 3). In preS1 promoter
(SP1; nt. 2682–2887) scattered nucleotide changes were
observed in isolates from all three groups but the most
noticeable mutation was at position nt. 2732 detected in one
IC (7.14%), eight CHB (61.53%) and three LC (23.07%), sug-
gesting its potential importance in the development of CHB
(PIC vs. CHB = 0.004). No signiﬁcant change was observed in
other HBV promoters.
HBV PreS/S ORF. The amino acid (aa) sequences of HBV sur-
face proteins (PreS1, PreS2 and S) deduced from the nucleo-
tide sequences revealed in-frame deletions, ranging from
single to 8 aa in four LC patients (30.76%) and one CHB
patient (7.69%), while deletions were conspicuously absent
among IC (Ptrend = 0.016). All deletions detected in LC were
mapped within the B-cell epitope (aa 120–145) of PreS2
while a single amino acid deletion (aa 94) in PreS1 within
overlapping B and T cell epitopes, was observed in an isolate
from CHB. The most notable amino acid substitutions
observed in PreS1 were A39R and S96A/T, both within
TABLE 2. Clinical, demographic and biochemical data of different categories of HBeAg-negative patients
IC (n = 16) CHB (n = 20) LC (n = 24) p value
Age (year), mean ± SD 46.44 ± 13.79 31.73 ± 10.67 42.73 ± 10.67 <0.0388$
Sex, M:F 9:5 13:7 17:7
ALT (IU/L), median (range) 31 (21–39) 47 (38–67) 89 (47–238) <0.0001$
AST (IU/L), median (range) 30 (24–44) 49 (45–95) 92 (51–265) <0.0001$
Total protein (g/dL), mean ± SD 6.68 ± 0.54 7.26 ± 0.35 7.58 ± 0.59 <0.0081$
Albumin (g/dL), mean ± SD 3.7 ± 0.47 3.75 ± 0.75 3.33 ± 0.68 <0.3012$
Total bilirubin (mg/dL), median (range) 0.89 (0.30–1.30) 0.80 (0.30–1.30) 1.8 (0.86–3.10) <0.0031$
Alkaline phosphatase (IU/L), median (range) 110 (42–407) 121 (42–263) 187 (78–344) <0.004*
INR, mean ± SD 1.11 ± 0.05 1.18 ± 0.05 1.35 ± 0.16 <0.0001$
HBV DNA (copies/mL), mean ± SD 3358 ± 3909 2.5 · 106 ± 3.5 · 106 9.6 · 105 ± 2.6 · 106 <0.0001*
SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; IU, international unit.
$One-way ANOVA p value.
*Kruskal–Wallis test p value.
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B-cell epitope regions, and were found in a signiﬁcantly high
proportion among CHB as compared with IC (PIC vs.
CHB < 0.05) (Table 3). Additionally, another mutation,
T118V/R, localized within the major hydrophilic region
(MHR; aa 100–169) of S was encountered at a high fre-
quency in LC (30.76%), followed by CHB (23.07%) and IC
(7.14%) (Ptrend = 0.016) (Table 3).
HBV · ORF. As HBV NRE/EnhII/BCP overlaps partially with
the HBx coding sequence, mutations at nucleotides
1635(A ﬁ T), 1753(T ﬁ C), 1762(A ﬁ T) and 1764
(G ﬁ A) induce substitutions in HBX at amino acid posi-
tions 88 (I ﬁ F), 127(I ﬁ T), 130(K ﬁ M) and 131(V ﬁ I)
respectively. Concurrently, a signiﬁcantly higher prevalence of
xI88F, and HBx130 + HBx131 double mutations were noted
in LC in comparison to IC (Table 3). Three other mutations,
namely P46S and T47S within the B-cell epitope region (aa
29–48) and A102V/T in the helper T-cell (TH) epitope (aa
91–105) of X, were observed with advancement of disease
severity, being most abundant in HBV from LC, followed by
CHB and IC (Ptrend < 0.05 for each; Table 3).
HBV precore (PC)/core ORF. The two mutations, G1896A and
G1899A, in the PC region frequently reported in e-negative
HBV variants were absent in HBV/D from IC. However, they
were noted in 15.38% and 7.69% of CHB, respectively, and
in 46.15% of LC (Table 3). Thus the combination of
G1896A+G1899A mutation might be a predictive risk factor
FIG. 1. Phylogenetic tree analysis of full-length sequences of 60 HBV isolates from chronic HBeAg-negative patients along with 50 reference
sequences of HBV belonging to different genotypes (A–J) derived from GenBank, including three sequences of HBV from non-human primates.
HBV sequences from GenBank are indicated by their genotypes followed by accession numbers and country of origin. The sequences determined
in the study are given by the isolate number followed by the clinical status of the patient (IC/CHB/LC) from whom it was derived. The phyloge-
netic tree was built using the Jukes Cantor and neighbour joining (NJ) method by MEGA software version5 and bootstrap resampling and recon-
struction were carried out 5000 times.
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for the development of cirrhosis from CHB (p 0.047). Vari-
abilities in TH epitopes, the cytotoxic T-cell (CTL) epitope
and the B-cell epitope of HBV core protein were high in LC
in comparison to IC (Table 4). Of particular importance
were substitutions S35A/T and E40D within the TH epitope
that had been found to be signiﬁcantly linked with the devel-
opment of CHB (Table 3). In addition, the mutation S183P
showed an increasing trend over the course of infection
from IC to LC (Ptrend = 0.005; Table 3).
HBV polymerase ORF. The sequences of the HBV polymerase
gene (except one) were found to have a wild-type reverse
transcriptase (RT) domain, which is the prime target of
antiviral therapy. As the PreS/S ORF completely overlaps the
polymerase gene, the deletions observed in the PreS1/PreS2
regions of ﬁve HBV strains mentioned above correspond
to deletions in the non-essential spacer regions of the poly-
merase.
Discussion
The present study demonstrated that the advancing clinical
stages of chronic e-negative infection correlate with a signiﬁ-
cant increase in the frequencies of mutations in the HBV/D
genome. A majority of these mutations were localized in the
TABLE 3. Frequencies of mutations across the complete genome of HBV of genotype D derived from different groups of
HBeAg-negative patients
Mutation site in HBV
Clinical categories of patients from whom
HBV was derived
Ptrend
test
Fisher exact test
Nucleotide substitution
mutation [location]
IC,
n = 14, (%)
CHB,
n = 13, (%)
LC,
n = 13, (%)
p1
(IC vs. CHB)*
p2
(CHB vs. LC)*
p3
(IC vs. LC)*
A1635T/G [NRE] 2 (14.28) 6 (46.15) 7 (53.85) 0.033 0.082 0.500 0.037
C1694T [EnhII] 1 (7.14) 6 (46.15) 3 (23.07) 0.317 0.029 0.952 0.269
A1762T [BCP] 0 4 (30.76) 7 (53.84) 0.002 0.041 0.214 0.002
G1764A [BCP] 0 4 (30.76) 7 (53.84) 0.002 0.041 0.214 0.002
A1762T+G1764A 0 4 (30.76) 7 (53.84) 0.002 0.041 0.214 0.002
C1773T [BCP] 0 4 (30.76) 5 (38.46) 0.016 0.041 0.500 0.016
A1762T+G1764A+ C1773T 0 2 (15.38) 5 (38.46) 0.009 0.222 0.189 0.015
G1896A [Pre-core] 0 2 (15.38) 6 (46.15) 0.003 0.222 0.101 0.006
G1899A [Pre-core] 0 1 (7.69) 6 (46.15) 0.002 0.481 0.037 0.006
G1896A+G1899A 0 0 4 (30.76) 0.009 1 0.047 0.040
C2732T [SPI] 1 (7.14) 8 (61.53) 3 (23.07) 0.334 0.004 0.992 0.269
Amino acid substitution
Mutation
X ORF
P46S 1 (7.14) 4 (30.76) 6 (46.15) 0.023 0.140 0.344 0.028
T47S 1 (7.14) 3 (23.07) 6 (46.15) 0.020 0.269 0.205 0.028
A102V/T 2 (14.28) 6 (46.15) 7 (53.84) 0.033 0.082 0.500 0.037
xI88F/V 2 (14.28) 6 (46.15) 7 (53.85) 0.033 0.082 0.500 0.037
xK130M 0 4 (30.76) 7 (53.84) 0.002 0.041 0.214 0.002
xV131I 0 4 (30.76) 7 (53.84) 0.002 0.041 0.214 0.002
Core ORF
c S35A/T 0 5 (38.46) 3 (23.07) 0.123 0.016 0.899 0.098
c E40D 1 (7.14) 7 (53.84) 4 (30.76) 0.166 0.011 0.945 0.140
c S183P 0 1 (7.69) 5 (38.46) 0.005 0.481 0.080 0.016
Surface ORF
D PreS 0 1 (7.69) 4 (30.76) 0.016 0.481 0.139 0.040
preS1 A39R 1 (7.14) 9 (69.23) 3 (23.07) 0.339 0.001 0.998 0.269
preS1 S96A/T 1 (7.14) 7 (53.84) 3 (23.07) 0.327 0.011 0.979 0.269
s T118V/R 1 (7.14) 3 (23.07) 4 (30.76) 0.016 0.481 0.161 0.041
*Fisher exact test p value; p<0.05 is indicated in bold.
TABLE 4. Frequencies of mutations in immune epitope regions of core ORF of HBV/D isolates from different clinical catego-
ries of HBeAg-negative patients
Clinical
categories
Regions of HBV core gene
Th epitopes CTL epitopes B-cell epitopes
35–45 48–69 18–27 84–101 76–89 105–116 130–135
IC (n = 14)
Frequency (%)
3
(21.42)
4
(28.57)
2
(14.28)
4
(28.57)
6
(42.85)
7
(50.00)
6
(42.85)
CHB (n = 13)
Frequency (%)
6
(46.15)
5
(38.46)
3
(23.07)
3
(23.07)
4
(30.76)
9
(69.23)
3
(23.07)
LC (n = 13)
Frequency (%)
7
(53.84)
7
(53.84)
6
(46.15)
5
(38.46)
6
(46.15)
9
(69.23)
8
(61.53)
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transcription regulatory regions (BCP/EnhII/NRE/SP1) and in
immunologically relevant sites. While some mutations
successively increased across the three phases IC, CHB and
LC, others were more important with a speciﬁc disease
phase.
Consistent with previous studies on HBV genotypes B and
C [15,16], our results indicated that BCP double mutation,
A1762T and G1764A were associated with increased risk of
severe liver disease in e-negative HBV/D-infected patients.
Another BCP mutation, C1773T, which had been previously
implicated in the development of cirrhosis in patients carry-
ing genotypes B and C [16], also showed an increased preva-
lence with progression of disease in subjects with HBV/D.
Interestingly, A1635T/G in NRE, C1694T in EnhII and
C2732T in SP1 found to have a signiﬁcant association with
clinical outcome in this study were not documented previ-
ously with respect to any genotype. However, a study by
Zhu et al. [17] on HBV/C derived from liver biopsy speci-
mens of chronic hepatitis B patients in China reported the
presence of mutation at 1635 but it did not correlate with
cirrhosis or HCC. The preferential selection of coding muta-
tions within epitope regions of HBV of genotypes B and C
during chronic infection had been reported earlier. HBeAg
seroconversion was found to be associated with an increased
frequency of mutations in CTL directed epitopes [18] while
a recent study highlighted an increased number of mutations
in CTL epitopes in cirrhosis and HCC groups regardless of
their HBeAg status [19]. Although we observed sequence
heterogeneity in CTL epitopes of HBV/D, no statistically sig-
niﬁcant association was found with any disease state. In hepa-
toma patients of Taiwan, where HBV/B and C prevail,
dominant mutations were detected within regions of aa 26–
45 in the B-cell epitope and 116–127 in the T-cell epitope in
HBx [20]. In contrast, our results indicated that variations in
HBx were most pronounced at aa 46 and 47 in the B-cell
epitope and at 102 in the TH epitope and occurred most fre-
quently among LC. Our data are in agreement with a past
study [21], demonstrating that HBV derived from anti-HBe-
positive subjects with active hepatitis harboured a greater
number of mutations in the TH epitope of the core protein
and a high rate of substitution (E ﬁ D) was noted at aa 40.
The PreS mutations, A2964C and T3116C, had been
reported to be associated with increased risk of cirrhosis in
HBV/C-infected patients [22]. The mutation A2964C corre-
sponds to substitution at amino acid 39 (K ﬁ N) within the
B-cell epitope of PreS1 in HBV/C. Mutation in this location
was found to be signiﬁcantly associated with the develop-
ment of CHB from IC in our study population, although the
amino acid change involved in HBV/D was different (A39R).
The other D-speciﬁc mutation in PreS1, S96A/T, also within
the B-cell epitope and increasingly present in CHB, has not
been reported before. An increased variability at aa 126 in
MHR of HBV/B had been reported during the progression of
chronic hepatitis B in Taiwanese patients [23]. However, in
the present study, the most signiﬁcant mutation in MHR that
was related to severity of e-negative infection was at position
118 (T118V/R). This mutation was also perceived in 6% of
the chronic carriers in Morocco [24]. Similar to prior studies
on HBeAg-negative patients infected with HBV of genotype
B or C [25], our results also suggested that deletion in the
preS region of HBV/D was an important predictor of cirrho-
sis. The only clinically important mutation in HBV/D found
outside the epitopic region that increased successively during
progression from IC through CHB to LC was S183P in
C-terminus of HBV core protein.
The clinical signiﬁcance of precore mutations G1896A and
G1899A remains controversial, as they were linked with
severe liver disease in some studies [26–28] while other
studies failed to conﬁrm the association [29,30]. Our data
indicated that the prevalence of both of these mutations and
also their combination was signiﬁcantly high in LC compared
with CHB and IC. Our result was also in accordance with a
previous report from northern India where PC mutants of
HBV were found to be associated with a more aggressive
course of liver disease [8].
Thus the present study has identiﬁed mutations in HBV/D
associated with different outcomes of chronic HBeAg-nega-
tive infection. The most important clinical implication of our
ﬁndings is the possibility that by tracking these candidate
viral genomic markers it may be possible to identify high-risk
individuals well before clinical diagnosis of advanced liver dis-
ease so that early interventions would greatly beneﬁt these
patients and help in decreasing the overall incidence of cir-
rhosis and eventually HCC. However, a major limitation of
our study is a small sample size and the use of a cross-sec-
tional design, making it difﬁcult to ascertain whether these
mutations preceded the development of advanced liver dis-
eases. Further large-scale prospective studies are needed to
validate these observations.
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